Stakeholder perspectives on interventions to improve HIV Pre-Exposure Prophylaxis uptake and continuation in Lesotho: A participant-ranked preferences study
============================================================================================================================================================

* Pascal Geldsetzer
* Joy J. Chebet
* Rachel P. Chase
* Tapiwa Tarumbiswa
* Chivimbiso Maponga
* Esther Mandara
* Till Bärnighausen
* Shannon A. McMahon

## Abstract

**Background** Low uptake and high discontinuation rates remain major obstacles to realizing the potential of Pre-Exposure Prophylaxis (PrEP) in changing the trajectory of the HIV epidemic in sub-Saharan Africa. Evidence on how PrEP could be successfully delivered has thus far mainly focused on key target groups rather than the general adult population. Set in the HIV-hyperendemic country of Lesotho, which is currently rolling out PrEP for the general adult population, this study aimed to determine stakeholders’ views on which are the most important barriers and most promising interventions to achieving high PrEP uptake and continuation.

**Methods and findings** We conducted a card sorting and ranking exercise with 155 local stakeholders to identify key barriers and interventions. Stakeholders were a purposive sample of PrEP policy makers and implementing partners (n=7), healthcare providers (n=51), and end-users (n=97). End-users included adults who were currently using PrEP (n=55), formerly using PrEP (n=36), and were offered PrEP by a healthcare provider but declined (n=6). Participants sorted pre-selected interventions and barriers to PrEP coverage into three piles – most, somewhat, and least important. After sorting, participants ranked interventions and barriers in the “most important” piles in ascending order of significance. Ranked preferences were analyzed as voting data to identify the smallest set of candidates for which each candidate in the set would win a two-candidate election against any candidate outside the set. Participants viewed a lack of PrEP awareness as the most important barrier to PrEP uptake for women, and a fear of HIV testing for men. Community-based HIV testing was ranked as the most promising intervention to improve PrEP uptake for both men and women. Perceived or experienced stigma was seen as an important barrier for PrEP continuation for both men and women, with an additional important barrier for men being daily activities that compete with the time or mental bandwidth needed to take a daily pill. Adherence counseling and multi-month PrEP prescriptions were seen as the most promising interventions to improve PrEP continuation.

**Conclusions** Our findings suggest community-based activities that generate PrEP demand (community-based HIV testing and mass media campaigns), reinforced with facility-based follow-up (counseling and multi-month prescription) could be promising interventions to improve PrEP uptake and continuation in PrEP programs that are aimed at the general adult population. The views of the wide range of stakeholders that participated in this study could provide a useful starting point for design and implementation choices of PrEP delivery programs for the general adult population.

## Introduction

Despite declines in infection and transmission rates over the last three decades, stagnating progress towards the goal of ending the HIV epidemic indicates a need to expand effective prevention programs to address current gaps (1). Interventions focusing solely on behavior change have demonstrated limited success in preventing HIV infection at the population level (2). Conversely, the use of antiretroviral (ARV) drugs have shown the capacity to acutely address the global HIV burden through a strategy that: 1) identifies those who are HIV positive with the aim of achieving viral load suppression among these patients through consistent use (3,4), and 2) provides once-daily oral Pre-Exposure Prophylaxis (PrEP) to those at substantial risk of acquiring HIV to prevent infection (5,6).

Clinical trials and demonstration projects have shown PrEP to be over 90% efficacious in preventing HIV infection when used consistently and as directed (7). However, the real-life effectiveness of PrEP is strongly dependent on adherence to PrEP [(7). Thus, both low uptake and discontinuation of PrEP remain substantial obstacles to achieving large-scale PrEP coverage (8–10). Previous studies have found that impediments that dissuade users from initial enrollment and sustained PrEP use include: 1) individual-level barriers, including fear of HIV testing, concern about adverse side effects, perception of low HIV infection risk, and disbelief in the drug’s efficacy (11–14); 2) social-level barriers encompassing concern over communicating about sexual matters with healthcare providers, perceived or experienced stigma surrounding PrEP use, limited decision-making capacity and lack of a robust social support system (11,13,15); and 3) structural barriers including, limited awareness of PrEP and access to PrEP-related services (11–14). Barriers specific to retention documented in the literature include challenges related to practical difficulties of taking a daily pill and life stressors that compete for time and mental bandwidth (16,17).

Interventions to improve PrEP uptake have focused on demand creation methods implemented through mass media campaigns and direct promotion in various settings, including the workplace, social gatherings and health facilities (17). For messaging to reach the grassroots, collaboration and partnerships with local leaders, as well as community- and faith-based organizations have been encouraged (12,15). Interventions to improve retention, on the other hand, have included increased contact between the health system and the user (through text messages and phone calls), increased adherence support (achieved through extended facility hours, adherence counseling, and support groups), incentivizing PrEP use, and providing multi-month prescriptions to reduce the burden placed on users (16,17).

Current evidence on barriers and interventions to improve PrEP coverage has mostly drawn on information from specific population groups classified as being at substantial risk for HIV infection (18). This has included Men who have Sex with Men (MSM), Injection Drug Users (IDUs), serodiscordant couples, and adolescent girls and women (19–24). At present, little evidence on interventions to achieve high PrEP coverage in the general population is available, particularly in sub-Saharan Africa (25–27). Using a novel participatory card sorting and ranking methodology and by studying the views of a broad set of stakeholders in Lesotho, the objective of this study was to inform PrEP implementation efforts for the general population. Specifically, this study aimed to determine stakeholders’ views on which are 1) the most important reasons for low uptake and discontinuation of PrEP, and 2) the most promising interventions for improving PrEP uptake and continuation.

## Methods

### Study setting and selection of study sites

The Lesotho Ministry of Health began offering PrEP as part of a comprehensive HIV prevention package in 2016, with the program focusing largely on serodiscordant couples (28). This approach was employed to address the generalized HIV epidemic in the country – the second highest global prevalence of HIV among adults aged 15-59 years (25.6%) (29). Since the PrEP program’s initiation in a subset of the country’s ten districts, it has been expanded to include all individuals at substantial risk of HIV infection (28). This is defined as populations with an HIV incidence rate of 3 per 100 person-years on a population level (28,30). Currently, the Ministry of Health is scaling up the PrEP program to reach all 10 districts in the country (28).

Our study was conducted in five districts where the PrEP program was initially implemented: Maseru, Leribe, Berea, Mafeteng and Mohales Hoek. Two healthcare facilities were identified as study sites in each district. To capture variation in setting, the study sites were purposively selected to include a range of PrEP client volumes, governmental versus private facilities, and rural versus urban areas.

### Study design and sampling

Data were collected between March and April 2019. Participants were identified based on their engagement with the national PrEP program and represented multiple levels of the health system – from policy makers to target end-users. Participants were purposively selected to participate in the study based on their expertise and experience with PrEP policy development, implementation, and/or PrEP use. The sampling method aimed to provide variation in perspective and viewpoints. The stakeholders along with their inclusion criteria and sampling strategy are summarized in Table 1.

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/T1)

Table 1: 
Summary of participant sampling strategies and inclusion criteria

### Card sorting and ranking exercise

The barriers and interventions to PrEP implementation that were presented to participants in this study are shown in Table S1 in the appendix. These barrier and intervention candidates were written on individual cards and presented to each participant during a one-on-one interview. The card sorting and ranking exercise had two steps (Figure 1). First, the sorting portion of the exercise sought to identify the most important barriers and most helpful interventions for the uptake and retention of PrEP for men and women in Lesotho from the participant’s perspective. Participants were asked to place barriers and interventions into three piles with pre-determined themes. For barriers, the piles were: 1) most important; 2) somewhat important; and 3) not important. Intervention piles were: 1) most helpful; 2) somewhat helpful; and 3) not helpful. To overcome literacy challenges and to ensure consistent interpretation across participants, research assistants presented each of the candidates on separate laminated cards and verbally explained the barrier/intervention through moderated facilitation. Second, in order to prioritize the most important barriers and most helpful interventions, participants ranked candidates under the “most important barrier” and “most helpful intervention” piles in ascending order, with the candidate ranked first being the most important barrier or most helpful intervention. Participants were prohibited from placing two or more barriers/interventions in the same position – that is, no ties were allowed. To gain gender-specific insight, each participant (regardless of their gender) was asked to sort and rank each set of barriers and interventions for men and women separately.

![Figure 1:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/12/06/2022.12.05.22283125/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/F1)

Figure 1: 
Schematic illustrating hypothetical card sorting into piles based on importance, and ranking of candidates in the ‘most important/helpful’ pile in ascending order

### Data management and quality control

Research assistants recorded each participant’s preferences physically on a paper guide, reviewed the data collected following each interview and asked for clarification from participants before their departure. A study investigator then reviewed all the research assistant questionnaires for accuracy and completeness. Participant responses were then entered into a Microsoft Excel spreadsheet. Two investigators independently reviewed entered data for inaccuracies, such as ties in ranking and other entry errors. Discrepancies were resolved by cross referencing with the physical questionnaires.

### Data analysis

Ranked preferences were treated like voting data, whereby each choice presented to a participant was considered a candidate running in an election. Candidates sorted into the “most important barrier” or “most helpful intervention” pile were pitted against each other in pairwise, head-to-head contests, with the participant’s vote going to the candidate they ranked higher. We identified the Smith set, which is the smallest set of candidates wherein each member in the set would win in a head-to-head election against any candidate outside of the set (31). The candidates in the Smith set would therefore be considered to have mutual majority. When there is only one candidate in the Smith set, this candidate is the Condorcet winner (32). The Condorcet winner, thus, is a candidate that would win against all the other candidates in a head-to-head election (32). In line with our objective of identifying the most highly prioritized barriers/interventions for PrEP coverage, a single winner was not essential. Rather, we aimed to identify highly prioritized interventions for PrEP coverage for further evaluation for financial, cultural and practical feasibility in improving PrEP coverage.

Ethical approval for this study was received from the research and ethics committee of the Lesotho Ministry of Health (ID03-2019), and the Heidelberg University ethical review board (S-865/2018). All participants provided written informed consent prior to participation in the study.

## Results

### Participant characteristics

We enrolled 150 participants in the study. Policy makers (n=4) included one participant involved in the oversight of the PrEP program at the national level, and three participants responsible for the dissemination and implementation of the PrEP program at the district level. On average, policy makers participating in the study had been in their current position for 6.5 years (range: 3-12 years) at the time of the interview. Implementing partners (n=3) included advisors and managers whose organizations were directly involved in the development of HIV-related policies and implementation of the national PrEP program. On average, the participating implementing partners had been in their current position for 2.7 years (range: 2-3 years). Due to their small number and similarities, policy makers and implementing partners were grouped for analyses. The demographic characteristics of all participants are detailed in Table 2.

View this table:
[Table 2:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/T2)

Table 2: 
Demographic characteristics of participants

### Barriers to PrEP uptake

When asked to sort and rank barriers related to PrEP uptake in Lesotho, participant prioritizations revealed differences in perceptions of obstacles that hinder men and women from initiating PrEP (see panel A, Figure 2). For men, overwhelmingly and across all respondent groups, participants ranked fear of HIV testing as the biggest barrier to initiating PrEP. For women, this was not prioritized as a prominent barrier. Instead, lack of awareness was prioritized as a substantial barrier for PrEP initiation for women. Among social-related barriers for PrEP initiation, discussing sexual matters with healthcare providers and perceived stigma were prioritized as a more important barrier for men than women. However, other socially relevant barriers, including lack of social support and limited decision-making power were more highly prioritized for women than men. Of note, concerns of side effects and the perception that PrEP is not effective were not prioritized as important barriers for uptake for neither men nor women.

![Figure 2:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/12/06/2022.12.05.22283125/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/F2)

Figure 2: 
Percent of participants that sorted each barrier into the “most important” and each intervention into the “most helpful” pile for men and women

In head-to-head pairwise elections (Table 3), fear of HIV testing emerged as the most important barrier to PrEP uptake for men. This candidate persisted as the winner in disaggregated data among all respondent groups, with the exception of PrEP decliners, for whom both fear of HIV testing and lack of awareness emerged as winners (as a Smith set). For women, lack of awareness was the winning candidate as biggest barrier to uptake. This barrier remained the winning candidate among all respondent groups, except among policy makers/implementing partners and healthcare providers. Lack of awareness and perceived stigma were the winners according to policy makers/implementing partners. Among healthcare providers, the winners were limited awareness, perceived sigma, and lack of social support emerged.

View this table:
[Table 3:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/T3)

Table 3: 
Barriers and intervention candidates ranked as most important / helpful for women and men

### Interventions to improve PrEP uptake

There were no substantial differences between the most highly participant-prioritized interventions for PrEP uptake by target population gender (Panel B, Figure 2). Participants ranked community-based HIV testing as the most helpful intervention for PrEP uptake for both men and women. Similarly, mass media campaigns were highly prioritized for both genders. However, there were some gendered differences in the less prioritized PrEP uptake interventions. Facility-based PrEP promotion, partnership with community leaders, CBOs, and religious leaders were prioritized higher as interventions for women than for men. PrEP promotion in local *shebeens* (bars) was more highly prioritized for men compared to women. Overall, the least prioritized intervention for PrEP uptake was partnership with traditional healers. In head-to-head pairwise elections and when pooling all participants (Table 3), community-based HIV testing emerged as the overall winner for the most helpful intervention to increase PrEP uptake for men and women.

### Barriers to PrEP retention

Participant prioritizations indicated that for both men and women in Lesotho, stigma and concern about side effects are important barriers to retention (Panel C, Figure 2). However, other social factors – such as social support and decision-making power – were prioritized more as barriers to PrEP adherence for women than men. Barriers that disrupt daily routines – such as factors of daily life and the daily medication regimen – were prioritized more for men than women. Furthermore, the perception that one is not at risk for HIV infection, and that PrEP is not efficacious, were ranked higher as a barrier for men. In head-to-head pairwise contests and when pooling all participants (Table 3), perceived and/or experienced stigma emerged as the biggest barrier to PrEP retention for both men and women.

### Interventions to increase PrEP retention

To encourage PrEP adherence and retention, participants prioritized intensive counseling and an increase in prescription quantity as the most helpful interventions for both men and women. In terms of sex, different modes of PrEP administration, peer counseling and the use of support groups were prioritized as being more helpful interventions for women compared to men. Conversely, extended healthcare facility hours was more highly prioritized for men than women. In head-to-head pairwise elections (Table 3), intensive counseling emerged as the most helpful intervention to increase PrEP retention for women. For men, a Smith set consisting of increase in prescription quantity and intensive counseling were the overall winning candidates.

## Discussion

This study employed participant-centered methodology to identify highly prioritized barriers and interventions for PrEP uptake and retention in Lesotho from various stakeholders. Our findings highlighted gendered differences for barriers to PrEP uptake, with our participants prioritizing low awareness for women and fear of HIV testing for men as the most important barrier. For both women and men, community-based HIV testing was prioritized as the most promising intervention to increase PrEP uptake, with mass media campaigns also ranked highly by participants. Once initiated on PrEP, our participants ranked perceived/experienced stigma as the most important contributor to discontinuation. For men, factors of daily life, such as travel and the inconveniences incurred by the need to take a pill every day, were also ranked highly. As a means to increase retention on PrEP, our participants prioritized intensive adherence counseling and increasing the amount of PrEP dispensed at each visit as interventions that would be most helpful.

Our findings demonstrate convergence across respondent groups – from policy makers to end-users – with regard to barriers that hinder PrEP uptake in Lesotho. In ranking salient barriers for PrEP retention, however, there was divergence; while stigma was highly prioritized across all groups, there were some differences in the ranking of other adherence barriers. Of note, PrEP end-users prioritized factors directly associated with taking PrEP – such as side effects, PrEP efficacy, and perception that they are not at risk – as being salient. These barriers were not prioritized by policy makers and implementing partners. Slight divergences in ranking among our participants are compelling for several reasons. First, they demonstrate the complexity around factors contributing to PrEP retention, illustrating that challenges for adherence are multifaceted, particularly for men. While there has been recent work done on PrEP adherence, few studies have focused exclusively on heterosexual African men (13,33,34). The studies that have, have done so in the context of men in a serodiscordant relationship (35,36). Second, this finding is indicative of the varied views held by end-users, healthcare providers, and policy makers. Research shows user concerns emerge from personal and lived experience, whereas implementing partners assess the situation from a birds-eye view (37,38). This gives credence to the importance of incorporating multiple viewpoints whilst developing an intervention – one which is acceptable to the end-user, while simultaneously being feasible from the financial and policy vantage points.

Social factors – including difficulty in discussing sexual matters with health providers, perceived/experienced stigma, and decision-making ability – were prioritized more highly as important barriers to PrEP uptake and retention, particularly for women, than those related to access, efficacy and side effects. Other studies have indicated the importance of considering the social context in the acceptability and adoption of health interventions (15,39). In these studies, the primary factors dissuading eligible individuals from initiating or adhering to PrEP were discussed in the context of others conflating PrEP use with being HIV positive, discouragement from others or a moral judgement about the reasons for the individual’s PrEP use (17,40). To alleviate trepidation arising from concern around stigma, user-centered studies have prioritized packaging and delivery methods, such preference for formulations that promote discrete use and are female initiated. These include the vaginal ring (41), and long-lasting injectables (42,43).

Fear of HIV testing emerged as a substantial barrier for initiating men on PrEP. Given frequent interactions with the health system – particularly during pregnancy, childbirth and the postpartum period – women have generally been shown to harbor less fear of testing compared to their male counterparts, but are still concerned about disclosing their status (44,45). As the first step in the PrEP cascade, HIV testing is essential in determining an individual’s eligibility for the drug (30). In other studies, fear of HIV testing is linked to concern for stigmatization, distress that the result will be positive, and apprehension over confidentiality (39,46–49). To encourage HIV testing and address testing-related concerns, interventions that normalize testing and are conducted in the community, or alone (self-tests) have demonstrated higher successes in increasing testing (50,51).

Perhaps our most relevant finding for the design and implementation of PrEP programs for the general population is the suggestion that interventions be brought closer to people – in this case, PrEP delivery within communities. By bringing PrEP and HIV testing services closer to the community, barriers related to transportation and distance are minimized (49). Nonetheless, study respondents also prioritized facility-based interventions as useful to encourage adherence, suggesting that a multipronged intervention both at the community and facility level can be employed in tandem. Facility-based interventions could include intensive adherence counseling and monitoring and multi-month PrEP prescriptions (36,52).

Our study has important limitations. First, due to logistical and sample size constraints, we were unable to conduct this study among a sample of participants that is representative of Lesotho’s population. Instead, we employed a purposive sampling strategy with the aim of including a wide range of stakeholders and, thus, views on PrEP delivery. Second, participants were limited by the barrier/intervention candidates presented to them. We sought to mitigate this limitation by inviting the inclusion of additional barriers or interventions at interview outset. However, none of the participants suggested additional candidates. Third, our sample size for policy makers, implementing partners, and PrEP decliners was small, making it difficult to generalize findings for these participant groups. We were limited by the number of individuals directly working on the PrEP program in Lesotho when selecting policy makers and implementing partners. Additionally, lack of official records for PrEP decliners limited our ability to actively recruit further participants into the study. Lastly, women were overrepresented in our study participants. This may be reflective of earlier iterations of the Lesotho PrEP program that targeted key populations, including serodiscordant couples, female sex workers, and adolescent girls and women.

## Conclusion

Our novel participant-centered ranking methodology offered rich insight from varying perspectives, and particularly from end-users whose opinions are not often considered in the development and implementation of health interventions (37). The views of this wide range of stakeholders could provide a useful starting point for design and implementation choices of PrEP delivery programs for the general adult population. Views and preferences may, however, vary by setting such that care should be taken in extrapolating any of our findings beyond the Lesotho context.

## Data Availability

A deidentified version of our dataset will be made available in a publicly accessible data repository upon acceptance of the manuscript for publication.

## Competing interests

There are no competing interests.

## Author contributions

PG, JJC, and SAM conceptualized the study. JJC, TT, CM, and EM organized and supervised the data collection activities. JJC and RPC analyzed the data. PG and JJC drafted the manuscript. All authors provided critical input to revisions of the manuscript. All authors have read and approved the final manuscript.

## Supplementary material

View this table:
[Table S1:](http://medrxiv.org/content/early/2022/12/06/2022.12.05.22283125/T4)

Table S1: 
Barrier and intervention candidates presented to participants during the card sorting and ranking exercise

## Acknowledgements

Our gratitude goes to the many participants from the five Lesotho districts who gave their time, expertise, and experience for this work. We thank the Ministry of Health for their continuous support throughout the preparation, data collection, and analysis of this work. We also thank all data collectors for their commitment and diligence.

## Footnotes

*   Sources of support: Alexander-von-Humboldt Foundation; Chan Zuckerberg Biohub

*   Received December 5, 2022.
*   Revision received December 5, 2022.
*   Accepted December 6, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)

## References

1.  1.UNAIDS. Global AIDS update: miles to go. Closing gaps breaking barriers righting injustices. Adoption and Fostering. 2018.
    
    

2.  2.Padian NS, McCoy SI, Karim SSA, Hasen N, Kim J, Bartos M, et al. HIV prevention transformed: The new prevention research agenda. The Lancet. 2011;378(9787):269–78.
    
    

3.  3.Bangsberg DR. Less Than 95% Adherence to Nonnucleoside Reverse-Transcriptase Inhibitor Therapy Can Lead to Viral Suppression. Clinical Infectious Diseases. 2006;43(7):939–41.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/507526&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16941380&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000240253200023&link_type=ISI) 

4.  4.Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine. 2002;17(5):377–81.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1046/j.1525-1497.2002.10644.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12047736&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000175882000010&link_type=ISI) 

5.  5.Mastro TD, Sista N, Abdool-Karim Q. ARV-based HIV prevention for women - Where we are in 2014. Journal of the International AIDS Society. 2014;17(3).
    
    

6.  6.Baeten JM, Haberer JE, Liu AY, Sista N. Pre-exposure prophylaxis for HIV prevention: Where have we been and where are we going? Journal of Acquired Immune Deficiency Syndrome. 2014;63(0 2):S122–9.
    
    

7.  7.Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Aids. 2016;30(12):1973–83.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/QAD.0000000000001145&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27149090&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

8.  8.Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. 2014;11(3):1–6.
    
    

9.  9.Celum CL, Delany-moretlwe S, Mcconnell M,  Rooyen H Van, Bekker L, Kurth A, et al. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. 2015;18(Suppl 3):1–10.
    
    

10. 10.Pyra MN, Haberer JE, Hasen N, Reed J, Mugo NR, Baeten JM. Global implementation of PrEP for HIV prevention: setting expectations for impact. Journal of the International AIDS Society. 2019;22(8):1–7.
    
    

11. 11.Corneli AL, McKenna K, Headley J, Ahmed K, Odhiambo J, Skhosana J, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. Journal of the International AIDS Society. 2014;17(3):1–8.
    
    

12. 12.Sowicz TJ, Teitelman AM, Coleman CL, Brawner BM. Considerations for Implementing Oral Preexposure Prophylaxis: A Literature Review. Journal of the Association of Nurses in AIDS Care. 2014;25(6):496–507.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jana.2014.07.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25305026&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

13. 13.Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4):1–18.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0131080&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25919488&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

14. 14.Peng P, Su S, Fairley CK, Chu M, Jiang S, Zhuang X, et al. A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis. AIDS and Behavior. 2018;22(4):1063–74.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

15. 15.Haire BG. Preexposure prophylaxis-related stigma: Strategies to improve uptake and adherence –a narrative review. HIV/AIDS - Research and Palliative Care. 2015;7:241–9.
    
    

16. 16.Marcus JL, Buisker T, Horvath T, Amico KR, Fuchs JD, Buchbinder SP, et al. Helping our patients take HIV pre-exposure prophylaxis (PrEP): A systematic review of adherence interventions. HIV Medicine. 2014;15(7):385–95.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/hiv.12132&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24580813&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

17. 17.Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence ? BMC Infectious Diseases. 2018;18(581).
    
    

18. 18.Koechlin FM, Fonner VA, Dalglish SL, O’Reilly KR, Baggaley R, Grant RM, et al. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS and Behavior. 2017;21(5):1325–35.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

19. 19.Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine. 2010 Nov 23;363(27):2587–99.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1011205&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21091279&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000285763700004&link_type=ISI) 

20. 20.Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine. 2012;367(5):423–34.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1110711&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22784038&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000307001900007&link_type=ISI) 

21. 21.Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine. 2012;367(5):399–410.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1108524&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22784037&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000307001900005&link_type=ISI) 

22. 22.Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine. 2012;367(5):411–22.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1202614&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22784040&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000307001900006&link_type=ISI) 

23. 23.Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Articles Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.
    
    

24. 24.Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine. 2015;372(6):509–18.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1402269&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25651245&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

25. 25.Calabrese SK, Underhill K, Earnshaw VA, Hansen NB, Kershaw TS, Magnus M, et al. Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. AIDS and Behavior. 2016;20(7):1499–513.
    
    

26. 26.McGillen JB, Anderson SJ, Hallett TB. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. Journal of the International AIDS Society. 2016;19(Suppl 6):1–8.
    
    

27. 27.Cowan F, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou F, Alary M. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19(21).
    
    

28. 28.Government of Lesotho. National guidelines on the use of antiretroviral therapy for HIV prevention and treatment. 2016.
    
    

29. 29.Lesotho Ministry of Health, Lesotho Bureau of Statistics, U.S President’s Emergency Plan for AIDS Relief, Centers for Disease Control and Prevention, ICAP Columbia University. Lesotho Population-Based HIV Impact Assessment: LePHIA 2016-2017: Summary sheet: Preliminary findings. 2017.
    
    

30. 30.World Health Organization. Guideline on When To Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization. 2015.
    
    

31. 31.Smith JH. Aggregation of preferences with variable electorate. Econometrica. 1973;41(6):1027–41.
    
    

32. 32.Fishburn PC. Social Choice Functions. SIAM Review. 1977;33(3):469–89.
    
    

33. 33.Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Micro M, et al. FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Preexposure Prophylaxis. Epidemiology and Prevention. 2014;66(3):324–31.
    
    

34. 34.Roberts ST, Haberer J, Celum C, Mugo N, Ware NC, Cohen CR, et al. Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes. 2016;73(3):313–22.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

35. 35.Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-exposure Prophylaxis (PrEP) for HIV Serodiscordant Couples. Journal of Acquired Immune Deficiency Syndrome. 2012;59(5).
    
    

36. 36.Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Medicine. 2013;10(9).
    
    

37. 37.Syvertsen JL, Robertson Bazzi AM, Scheibe A, Adebajo S, Strathdee SA, Wechsberg WM. The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers. African journal of reproductive health. 2014;18(3 Spec No):74–83.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26050379&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

38. 38.Kippax S. Effective HIV prevention: The indispensable role of social science. Journal of the International AIDS Society. 2012;15(2):1–8.
    
    

39. 39.Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: Results of a consultation with community stakeholders. BMC Health Services Research. 2014;14(1):1–12.
    
    

40. 40.Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. Journal of Acquired Immune Deficiency Syndromes. 2016;71(4):452–61.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/QAI.0000000000000880&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

41. 41.Van Der Straten A, Shapley-Quinn MK, Reddy K, Cheng H, Etima J, Woeber K, et al. Favoring “peace of Mind”: A Qualitative Study of African Women’s HIV Prevention Product Formulation Preferences from the MTN-020/ASPIRE Trial. AIDS Patient Care and STDs. 2017;31(7):305–14.
    
    

42. 42.Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M, et al. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. Medical Decision Making. 2018;38(1):120–33.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

43. 43.Minnis AM, Browne EN, Boeri M, Agot K, Van Der Straten A, Ahmed K, et al. Young women’s stated preferences for biomedical HIV prevention: Results of a discrete choice experiment in Kenya and South Africa. Journal of Acquired Immune Deficiency Syndromes. 2019;80(4):394–403.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

44. 44.Pool R, Nyanzi S, Whitworth JAG. Attitudes to voluntary counselling and testing for HIV among pregnant women in rural south-west UGANDA. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2001;13(5):605–15.
    
    

45. 45.Okonkwo KC, Reich K, Alabi AI, Umeike N, Nachman SA. An evaluation of awareness: Attitudes and beliefs of pregnant Nigerian women toward voluntary counseling and testing for HIV. AIDS Patient Care and STDs. 2007;21(4):252–60.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/apc.2006.0065&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17461720&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000246011800005&link_type=ISI) 

46. 46.Meiberg AE, Bos AER, Onya HE, Schaalma HP. Fear of stigmatization as barrier to voluntary HIV counselling and testing in South Africa. East African journal of public health. 2008;5(2):49–54.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19024410&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

47. 47.Day JH, Miyamura K, Grant AD, Leeuw A, Munsamy J, Baggaley R, et al. Attitudes to HIV voluntary counselling and testing among mineworkers in South Africa: Will availability of antiretroviral therapy encourage testing? AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2003;15(5):665–72.
    
    

48. 48.Jürgensen M, Tuba M, Fylkesnes K, Blystad A. The burden of knowing: Balancing benefits and barriers in HIV testing decisions. A qualitative study from Zambia. BMC Health Services Research. 2012;12(1):10–3.
    
    

49. 49.Ostermann J, Njau B, Brown DS, Mühlbacher A, Thielman N. Heterogeneous HIV testing preferences in an urban setting in tanzania: Results from a discrete choice experiment. PLoS ONE. 2014;9(3).
    
    

50. 50.Makusha T, Knight L, Taegtmeyer M, Tulloch O, Davids A, Lim J, et al. HIV self-testing could “revolutionize testing in South Africa, but it has got to be done properly”: Perceptions of key stakeholders. PLoS ONE. 2015;10(3):1–10.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0131080&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25919488&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 

51. 51.Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L, et al. Supervised and Unsupervised Self-Testing for HIV in High- and Low-Risk Populations: A Systematic Review. PLoS Medicine. 2013;10(4).
    
    

52. 52.Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: A systematic review of evaluation studies. The Lancet Infectious Diseases. 2011;11(12):942–51.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(11)70181-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22030332&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F12%2F06%2F2022.12.05.22283125.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000297494300021&link_type=ISI)